The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

In a late-stage clinical trial, a drug similar to Ozempic was shown to reduce body mass index in kids ages 6 to 11 with ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...